Abstract
Background: Malnutrition is seen in COVID-19 patients, and reducing malnutrition with appropriate therapies may improve these patients' health. this case-control study aimed to assess and compare serum levels of some inflammatory factors and oxidative stress and appetite in COVID-19 patients with respiratory infections that receive glutamine treatment with a control group. Method: In this study, patients who consented to use glutamine were considered as the case group and other patients who did not use glutamine were considered as a control group. Twenty-seven Covid-19 patients (10 female, 48.5 ± 9.1) using L-Glutamine and 27 Covid-19 patients (12 female, 48.8 ± 4.6) with similar age, gender, and clinical status were included in the study. For five days, the case group was given 10g/day of glutamine supplement. At the end of the fifth day, blood samples were taken again to test for serum levels of IL1β, tumor necrosis factor-alpha, malondialdehyde, and total antioxidant capacity, then all data were analyzed. Results: Serum levels of beta-1 interleukin, tumor necrosis factor-alpha, and hs-CRP were significantly reduced with five days of glutamine supplementation (p <0.05), and patients' appetite during five days of glutamine supplementation compared with the control group had a significant increase (p <0.05. Conclusion: Glutamine supplementation in COVID-19 patients with respiratory infection significantly reduces serum levels of interleukin-1 beta, hs-CRP, and tumor necrosis factor-alpha and significantly increases appetite, so glutamine supplementation may be useful for COVID-19 patients in the hospital.
The Effect of Glutamine Supplementation on Serum Levels of Some Inflammatory Factors, Oxidative Stress, and Appetite in COVID-19 Patients: A Case-Control Study
